Natixis Advisors LLC Invests $288,000 in Simulations Plus, Inc. (NASDAQ:SLP)

Natixis Advisors LLC bought a new position in shares of Simulations Plus, Inc. (NASDAQ:SLP - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 10,337 shares of the technology company's stock, valued at approximately $288,000. Natixis Advisors LLC owned 0.05% of Simulations Plus as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in SLP. Jones Financial Companies Lllp grew its holdings in Simulations Plus by 53.6% during the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company's stock valued at $34,000 after purchasing an additional 427 shares during the period. Quantbot Technologies LP bought a new position in shares of Simulations Plus during the third quarter worth $59,000. AlphaQuest LLC grew its holdings in shares of Simulations Plus by 502.9% in the 4th quarter. AlphaQuest LLC now owns 2,689 shares of the technology company's stock valued at $75,000 after buying an additional 2,243 shares during the period. US Bancorp DE increased its position in shares of Simulations Plus by 14.3% in the 4th quarter. US Bancorp DE now owns 5,687 shares of the technology company's stock valued at $159,000 after buying an additional 713 shares in the last quarter. Finally, Olympiad Research LP acquired a new stake in Simulations Plus during the 4th quarter worth $211,000. Institutional investors own 78.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. KeyCorp boosted their target price on Simulations Plus from $35.00 to $37.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. William Blair reiterated an "outperform" rating on shares of Simulations Plus in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Simulations Plus has an average rating of "Moderate Buy" and an average target price of $49.40.

Remove Ads

Simulations Plus Trading Up 2.8 %

Shares of Simulations Plus stock traded up $0.67 during trading on Wednesday, reaching $24.77. The stock had a trading volume of 229,794 shares, compared to its average volume of 174,512. The company has a market capitalization of $497.68 million, a price-to-earnings ratio of 61.93 and a beta of 0.89. The stock has a fifty day moving average price of $30.38 and a two-hundred day moving average price of $30.38. Simulations Plus, Inc. has a 52 week low of $23.44 and a 52 week high of $51.22.

Insider Activity at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the sale, the director now directly owns 3,402,584 shares of the company's stock, valued at $115,381,623.44. The trade was a 0.58 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 19.40% of the stock is owned by insiders.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.